International Journal of Obesity
SEARCH     advanced search my account e-alerts subscribe register
Journal home
Advance online publication
Current issue
Archive
Press releases
For authors
For referees
Contact editorial office
About the journal
For librarians
Subscribe
Advertising
naturereprints
Contact Springer Nature
Customer services
Site features
NPG Subject areas
Access material from all our publications in your subject area:
Biotechnology Biotechnology
Cancer Cancer
Chemistry Chemistry
Dentistry Dentistry
Development Development
Drug Discovery Drug Discovery
Earth Sciences Earth Sciences
Evolution & Ecology Evolution & Ecology
Genetics Genetics
Immunology Immunology
Materials Materials Science
Medical Research Medical Research
Microbiology Microbiology
Molecular Cell Biology Molecular Cell Biology
Neuroscience Neuroscience
Pharmacology Pharmacology
Physics Physics
Browse all publications
 
August 2001, Volume 25, Number 8, Pages 1129-1135
Table of contents    Previous  Abstract  Next   Full text  PDF
Paper
Conjugated linoleic acid (CLA) reduced abdominal adipose tissue in obese middle-aged men with signs of the metabolic syndrome: a randomised controlled trial
U Risérus, L Berglund and B Vessby

Clinical Nutrition Research Unit, Department of Public Health and Caring Sciences/Geriatrics, Faculty of Medicine, Uppsala University, Uppsala, Sweden

Correspondence to: U Risérus, Clinical Nutrition Research Unit, Department of Public Health and Caring Sciences/Geriatrics, Faculty of Medicine, Uppsala University, Box 609, 751 25 Uppsala, Sweden. E-mail: ulf.riserus@geriatrik.uu.se

Abstract

BACKGROUND: Abdominal obesity is strongly related to metabolic disorders. Recent research suggests that dietary conjugated linoleic acid (CLA) reduces body fat and may improve metabolic variables in animals. The metabolic effects of CLA in abdominally obese humans have not yet been tested.

OBJECTIVE: To investigate the short-term effect of CLA on abdominal fat and cardiovascular risk factors in middle-aged men with metabolic disorders.

METHODS: Twenty-five abdominally obese men (waist-to-hip ratio (WHR), 1.05±0.05; body mass index (BMI), 32±2.7 kg/m2 (mean±s.d.)) who were between 39 and 64-y-old participated in a double-blind randomised controlled trial for 4 weeks. Fourteen men received 4.2 g CLA/day and 10 men recieved a placebo. The main endpoints were differences between the two groups in sagittal abdominal diameter (SAD), serum cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, free fatty acids, glucose and insulin.

RESULTS: At baseline, there were no significant differences between groups in anthropometric or metabolic variables. After 4 weeks there was a significant decrease in SAD (cm) in the CLA group compared to placebo (P=0.04, 95% CI; -1.12, -0.02). Other measurements of anthropometry or metabolism showed no significant differences between the groups.

CONCLUSIONS: These results indicate that CLA supplementation for 4 weeks in obese men with the metabolic syndrome may decrease abdominal fat, without concomitant effects on overall obesity or other cardiovascular risk factors. Because of the limited sample size, the effects of CLA in abdominal obesity need to be further investigated in larger trials with longer duration.

International Journal of Obesity (2001) 25, 1129-1135

Keywords

conjugated linoleic acid (CLA); abdominal obesity; abdominal sagittal diameter; metabolic syndrome; cardiovascular risk factors; randomised controlled trial (RCT)

Received 4 February 2000; revised 31 July 2000; accepted 7 September 2000
August 2001, Volume 25, Number 8, Pages 1129-1135
Table of contents    Previous  Abstract  Next   Full text  PDF